Abstracts tagged "Biologics"

Abstract Number: 502 • 2013 ACR/ARHP Annual Meeting
Early Introduction Of Biologic Treatment Is An Important Predictor Of Sustained Favorable Outcome Including Clinical Remission In Early Arthritis But Not Of Sustained Favorable Outcome On Structure and Function Only: Results From The Espoir Cohort
Cécile Gaujoux-Viala¹, Laure Gossec², Maxime Dougados³, Francis Guillemin⁴ and Bruno Fautrel⁵, ¹EA 2415, Montpellier I University, Nîmes University Hospital, Rheumatology Department, Nîmes, France, ²Rheumatology, Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France, ³Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁴CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ⁵Paris 6 – Pierre et Marie Curie University; AP-HP, Rheumatology, Pitié-Salpêtrière Hospital, - GRC-UPMC 08 – EEMOIS, Paris, France
Background/Purpose: The relevant elements to evaluate health states in RA should include remission, good functional ability and structural stability [1]. The concept of favorable outcome…
Abstract Number: 194 • 2013 ACR/ARHP Annual Meeting
Team Managed Care From a Patient’s Perspective: A Study Of Biological Patients At a Canadian Centre
Dawn Heap¹, Margaret Saldanha¹, Melissa Deamude¹, Cynthia Mech², Helena Ross¹, Kathy Kislinsky¹, Lauri Vanstone³, Arthur N. Lau⁴ and William G. Bensen⁵, ¹Dr. William G. Bensen, Rheumatology Health Team, St. Joseph's Hospital Hamilton, Hamilton, ON, Canada, ²Dr. William G. Bensen, Rheumatology Health Team, Dr. Bensen's Rheumatology Clinic, Hamilton, ON, Canada, ³Dr. William Bensen Rheumatology Biologic Clinic, Rheumatology Health Team, Hamilton, ON, Canada, ⁴Rheumatology and Clinical Epidemiology, Division of Rheumatology, McMaster University, Hamilton, ON, Canada, ⁵Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada
Background/Purpose: In Canada, there is a widening care gap in Inflammatory Arthritis due to the increased aging population, higher disease prevalence, dwindling numbers of practicing…
Abstract Number: L11 • 2012 ACR/ARHP Annual Meeting
First in Patient Study of Anti-GM-CSF Monoclonal Antibody (MOR103) in Active Rheumatoid Arthritis: Results of a Phase 1b/2a Randomized, Double-Blind, Placebo-Controlled Trial
Frank Behrens¹, Mikkel Ostergaard², Rumen Stoilov³, Piotr Wiland⁴, Thomas W. Huizinga⁵, Vadym Y. Berenfus⁶, Paul-Peter Tak⁷, Stoyanka Vladeva⁸, Juergen Rech⁹, Andrea Rubbert-Roth¹⁰, Mariusz Korkosz¹¹, Dmitriy Rekalov¹², Igor A. Zupanets¹³, Bo J. Ejbjerg¹⁴, Jens Geiseler¹⁵, Julia Fresenius¹⁵, Roman P. Korolkiewicz¹⁶, Arndt J. Schottelius¹⁶ and Harald Burkhardt¹, ¹CIRI /Div. of Rheumatology, Goethe-University, Frankfurt/Main, Germany, ²Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, ³Clinic of rheumatology, University Hospital (MHAT) St. Ivan Rilski, Sofia, Bulgaria, ⁴Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Occupational Diseases, Regional Clinical Hospital, Donetsk, Ukraine, ⁷Academic Medical Center / currently also GlaxoSmithKline, Amsterdam, Netherlands, ⁸Second Internal Clinic UMHAT Stara Zagora, Stara Zagora, Bulgaria, ⁹Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ¹⁰Internal Medicine I, University of Cologne, Cologne, Germany, ¹¹Malopolskie Centrum Medyczne, Krakow, Poland, ¹²Department of Internal Diseases, Zaporizhzhia Regional Hospital, Zaporozhe, Ukraine, ¹³Clinical and Diagnostics Centre of National Pharmaceutical University MOH of Ukraine, Kharkiv, Ukraine, ¹⁴Slagelse Sygehus, Slagelse, Denmark, ¹⁵Asklepios Clinic Munich-Gauting, Gauting, Germany, ¹⁶Development, MorphoSys AG, Martinsried/Planegg, Germany
Background/Purpose: MOR103, a human mAb targeting GM-CSF, is being evaluated for treatment of rheumatoid arthritis (RA). Pre-clinical studies on cytokine function and investigations in experimental…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].